Patents by Inventor Alison Joly
Alison Joly has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6781000Abstract: &agr;-ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having the following formula: wherein X2 is Ar or Ar—X3 wherein X3 is is —C═O, or —CH2CO—, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls; R1, and R2 are each individually selected from the side chains of the known natural &agr;-amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl; X1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and wherein X4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and R3 is selected from the known natural &agr;-amino acids, unnatural amino acidsType: GrantFiled: July 19, 1999Date of Patent: August 24, 2004Assignee: CV Theurapeutics, Inc.Inventors: Lisa Wang, Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Michael M Wick
-
Patent number: 6709855Abstract: The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.Type: GrantFiled: December 15, 1999Date of Patent: March 23, 2004Assignee: Scios, Inc.Inventors: Lawrence W. Stanton, R. Tyler White, Deborah L. Damm, John A. Lewicki, Alison Joly, George F. Schreiner
-
Patent number: 6686354Abstract: The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.Type: GrantFiled: December 27, 2001Date of Patent: February 3, 2004Assignee: Scios, Inc.Inventors: Alison Joly, George F. Schreiner, Lawrence W. Stanton, R. Tyler White
-
Patent number: 6630297Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.Type: GrantFiled: November 7, 2002Date of Patent: October 7, 2003Assignee: Exelixis, Inc.Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
-
Publication number: 20030078382Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.Type: ApplicationFiled: November 7, 2002Publication date: April 24, 2003Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
-
Publication number: 20030032637Abstract: The invention concerns the use of agonists and antagonists of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.Type: ApplicationFiled: December 27, 2001Publication date: February 13, 2003Inventors: Alison Joly, George F. Schreiner, Lawrence W. Stanton, R. Tyler White
-
Patent number: 6515109Abstract: Human Ect2 polypeptide, fragments and derivatives, along with vectors and host cells for expression and production of Ect2 polypeptide are provided. Various methods of screening for agents that modulate interaction of Ect2 with an Ect2 binding agent, including high throughput methods, are also provided.Type: GrantFiled: October 12, 2001Date of Patent: February 4, 2003Assignee: Exelixis, Inc.Inventors: Michael Martin Ollmann, Kevin Patrick Keegan, Thomas J. Stout, David Matthews, Alison Joly
-
Publication number: 20030008864Abstract: The invention concerns the use of ligands of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of diseases involving cyst formation and in particular polycystic kidney disease. The invention further concerns the treatment of hypertension accompanying polycystic kidney disease, and pharmaceutical compositions and articles of manufacture for the treatment or diagnosis of the target disease or condition.Type: ApplicationFiled: April 30, 2002Publication date: January 9, 2003Inventors: George F. Schreiner, Alison Joly, Lawrence W. Stanton, R. Tyler White
-
Patent number: 6380183Abstract: The invention concerns the use of ligands of peripheral-type benzodiazepine receptors (PTBR) in the diagnosis and treatment of diseases involving cyst formation and in particular polycystic kidney disease. The invention further concerns the treatment of hypertension accompanying polycystic kidney disease, and pharmaceutical compositions and articles of manufacture for the treatment or diagnosis of the target disease or condition.Type: GrantFiled: December 15, 1999Date of Patent: April 30, 2002Assignee: Scios, Inc.Inventors: George F. Schreiner, Alison Joly, Lawrence W. Stanton, R. Tyler White
-
Patent number: 6342495Abstract: The invention concerns the use of agonists and antagonists of peripheral-type benzodiazcpine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.Type: GrantFiled: December 15, 1999Date of Patent: January 29, 2002Assignee: Scios, Inc.Inventors: Alison Joly, George F. Schreiner, Lawrence W. Stanton, R. Tyler White
-
Patent number: 6117887Abstract: This invention is novel indanone compositions useful for inhibiting cell proliferation disorders in mammals.Type: GrantFiled: June 2, 1998Date of Patent: September 12, 2000Assignee: CV Therapeutics, Inc.Inventors: Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Marek G. Nelson, Michael M. Wick
-
Patent number: 6075150Abstract: .alpha.-ketoamide compounds useful for treating disorders mediated by 20S proteasome in mammals having the following formula: wherein X.sub.2 is Ar or Ar--X.sub.3 wherein X.sub.3 is --C.dbd.O, or --CH.sub.2 CO--, and wherein Ar is phenyl, substituted phenyl, indole, substituted indoles, and any other heteroaryls; R.sub.1, and R.sub.2 are each individually selected from the side chains of the known natural .alpha.-amino acids and unnatural amino acids, hydrogen, 1-10 carbon linear and branched alkyl, 1-10 carbon linear and branched substituted alkyl, aryl, substituted aryl, 1-10 carbon linear, branched substituted aryl, alkoxyaryl, 3-8 carbon cycloalkyl, heterocycle substituted heterocycle, heteroaryl and substituted heteroaryl; X.sub.1 is selected from hydroxide, monoalkylamino, dialkylamino, alkoxide, arylkoxide and ##STR1## wherein X.sub.4 is hydroxide, arylamino, monoalkylamino, dialkylamino, alkoxide, or arylalkoxide; and R.sub.3 is selected from the known natural .alpha.Type: GrantFiled: January 26, 1998Date of Patent: June 13, 2000Assignee: CV Therapeutics, Inc.Inventors: Lisa Wang, Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Michael M Wick
-
Patent number: 5834487Abstract: This invention is a method for inhibiting cell proliferation using indanones.Type: GrantFiled: September 24, 1996Date of Patent: November 10, 1998Assignee: CV TherapeuticsInventors: Robert T. Lum, Steven R. Schow, Alison Joly, Suresh Kerwar, Marek G. Nelson, Michael M. Wick